[{"Assets_0_Q3_USD":716186000.0,"CommonStockSharesOutstanding_0_Q3_shares":41167942.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-21393000.0,"NetIncomeLoss_1_Q3_USD":-54516000.0,"NetIncomeLoss_3_Q3_USD":-95223000.0,"StockholdersEquity_0_Q3_USD":319065000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":40706000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":120475000.0,"Ticker":"TVTX","CIK":"1438533","name":"RETROPHIN, INC.","OfficialName":"Travere Therapeutics Inc. Common Stock","form":"10-Q","period":"20180930","fy":"2018.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1905907401.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20181101"}]